Plus Therapeutics (NASDAQ:PSTV) Stock Price Up 2.9%

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) rose 2.9% during trading on Thursday . The company traded as high as $1.81 and last traded at $1.80. Approximately 34,888 shares traded hands during trading, a decline of 38% from the average daily volume of 56,428 shares. The stock had previously closed at $1.75.

Plus Therapeutics Stock Up 2.9 %

The stock has a market cap of $10.26 million, a PE ratio of -0.59 and a beta of 0.54. The business’s fifty day moving average is $1.92 and its 200 day moving average is $1.92.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.34. The firm had revenue of $1.68 million for the quarter. Plus Therapeutics had a negative net margin of 193.49% and a negative return on equity of 805.57%. During the same period in the prior year, the firm posted ($2.10) EPS.

Insiders Place Their Bets

In other Plus Therapeutics news, CEO Marc H. Hedrick bought 12,255 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was bought at an average price of $2.04 per share, for a total transaction of $25,000.20. Following the completion of the transaction, the chief executive officer now owns 12,425 shares in the company, valued at approximately $25,347. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders acquired 26,961 shares of company stock worth $55,000. Insiders own 2.32% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.